Omnicell (NASDAQ:OMCL) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of Omnicell (NASDAQ:OMCL) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning.

A number of other analysts have also issued reports on OMCL. JPMorgan Chase & Co. lifted their target price on Omnicell from $26.00 to $37.00 and gave the stock a neutral rating in a research report on Friday, August 23rd. Benchmark restated a buy rating and issued a $38.00 price target on shares of Omnicell in a research note on Monday, July 15th. Barclays raised Omnicell from an underweight rating to an equal weight rating and boosted their price objective for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Bank of America increased their target price on Omnicell from $34.00 to $44.00 and gave the stock a buy rating in a report on Friday, August 2nd. Finally, Wells Fargo & Company boosted their price target on Omnicell from $26.00 to $30.00 and gave the company an equal weight rating in a report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Omnicell presently has an average rating of Moderate Buy and a consensus price target of $37.83.

Omnicell Stock Up 0.8 %

NASDAQ OMCL opened at $43.16 on Wednesday. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $56.06. The business has a 50 day moving average price of $37.42 and a two-hundred day moving average price of $31.63. The stock has a market cap of $1.98 billion, a PE ratio of -93.83, a P/E/G ratio of 47.48 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The business had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The business’s revenue for the quarter was down 7.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.29 earnings per share. As a group, sell-side analysts predict that Omnicell will post 0.64 EPS for the current fiscal year.

Institutional Trading of Omnicell

A number of institutional investors and hedge funds have recently made changes to their positions in OMCL. Victory Capital Management Inc. grew its position in Omnicell by 465.1% in the 4th quarter. Victory Capital Management Inc. now owns 44,766 shares of the company’s stock worth $1,685,000 after purchasing an additional 36,844 shares during the last quarter. M&T Bank Corp increased its stake in shares of Omnicell by 16.0% during the fourth quarter. M&T Bank Corp now owns 9,570 shares of the company’s stock valued at $360,000 after acquiring an additional 1,321 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Omnicell by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 483,443 shares of the company’s stock worth $18,192,000 after buying an additional 32,548 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Omnicell by 2.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,067,516 shares of the company’s stock valued at $40,173,000 after acquiring an additional 21,798 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Omnicell by 106.1% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 16,428 shares of the company’s stock valued at $618,000 after purchasing an additional 8,457 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.